STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (December 2025)

44 slides from STRATA Skin Sciences's investor presentation, Dec 17, 2025

  1. Slide 1: Driving Value in Therapeutic and Aesthetic Dermatology

    Investor Presentation December 2025 Driving Value in Therapeutic and Aesthetic Dermatology NASDAQ: SSKN

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be

  3. Slide 3: Investment Highlights

    Investment Highlights 3 Global leader in advanced laser and light-based devices delivering unmatched efficacy and safety for serious skin disorders Existing Business is Operationally Cashflow Positive Cash from operations in 2024 was $0.2M Adjusting for 1x other income from the CARES Act of $0.9M an

  4. Slide 4: What We Do

    What We Do 4 The XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat multiple autoimmune disease conditions (e.g. Psoriasis, Vitiligo).1-3* Quick and virtually painless without the troublesome side effects of other treatment options, it’s simply a better way to long

  5. Slide 5: Key Metrics

    Key Metrics 3 Stock Symbol NASDAQ: SSKN Stock Price (as of 12/8/25) $1.38 Shares Outstanding (as of 9/30/25) 4.2M Market Cap $8.2M Cash & Equivalents* $7.1M Debt* $15.3M Enterprise Value $16.4M Options* Warrants* 725,976 @ $6.13 WAEP 80,000 @ $8.80 WAEP Inside Ownership (%): 27% * As of 9/30/2025

  6. Slide 6: Business Model

    Business Model Recurring Revenue Business Model Revenue achieved through fee-per-use-based recurring procedures Reimbursed per procedure by Medicare and private payers Partnership - Recurring revenue driven by services that include turnkey practice solutions: No upfront capital expense DTC marketing

  7. Slide 7: ~1,000 Membership Agreements with Dermatology Providers Across the U.S.

    ~1,000 Membership Agreements​ with Dermatology Providers Across the U.S. 7 Overview 838 Partner XTRAC® clinics + >150 sold XTRAC® devices 161 TheraClear®X clinics 5 Regions / 22 Sales Territories / 1 National Accounts Manager / National Capital Manager 14 Field Service Techs In-house call center and

  8. Slide 8: XTRAC Adds Reimbursed Recurring Revenue for Dermatology Partners

    XTRAC® Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners 8 1 Specific Medicare payment rates vary depending on geographic indices assigned by Medicare. 2 At 20 (or 30) treatments per week, this represents 10 (or 15) patients in treatment (two treatments per week) at any one tim

  9. Slide 9: TheraClear X Adds Reimbursed Recurring Revenue for Dermatology Partners

    TheraClear®X Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners 9 1 Specific Medicare payment rates vary depending on geographic indices assigned by Medicare. Cpt Code Description 2025 National Average Medicare Payment Rate1 10040 Acne Surgery, which Involves the opening or remo

  10. Slide 10: Financial Metrics

    Financial Metrics 10 (All numbers below in $'000s except for U.S. Installed Base) *G&A reduced by ~$1.8M for 1x accrual of state sales tax

  11. Slide 11: Diverse Dermatology Market Opportunities

    Diverse Dermatology Market OpportunitiesPsoriasis - $20.1B1, Vitiligo - $1.2B2, Eczema - $11.8B3, Acne - $5.5B4 11 30M Patients in the U.S. Psoriasis – 8M / Vitiligo - 5M / Eczema - 18M Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected Fortune Bu

  12. Slide 12: STRATA – Expansion and Growth

    STRATA – Expansion and Growth Leverage Strata’s Unique and Proven Business Model Best-in-class devices Recurring revenue driven by DTC and internally-driven, growing installed base Turn-key services suite for practices without an upfront capital spend Elevate 360 Consulting - Optimizing growth throu

  13. Slide 13: Newly Expanded Indications & Enhanced Reimbursement Unlocking Growth

    Newly Expanded Indications & Enhanced Reimbursement Unlocking Growth 13 May 2025: CPT ® Editorial Summary of Panel Actions | AMA AMA accepted CPT code revision is effective from 1/1/202 Triples Strata’s XTRAC Addressable Patient Population From ~10M (psoriasis only) to 30M+ patients covering all Inf

  14. Slide 14: Value Drivers: 2025 Initiatives To Increase Growth In Recurring Revenue

    Value Drivers 2025 Initiatives To Increase Growth In Recurring Revenue Per Device In The U.S. Market 14 Emphasis on higher per practice performance through improved patient lead-to-procedure conversion and high touch, value-add support services i.e., reimbursement administration, scheduling, and enh

  15. Slide 15: Turn-Key Solutions to Ensure Practice Success

    Turn-Key Solutions to Ensure Practice Success 15 No upfront capital expense; fee-per-use business model Complete business solution includes a suite of value-added support services to maximize practice’s success Clinical Support Reimbursement Support Call Center Support Field Service Support Consumab

  16. Slide 16: Unique Go-to-Market Strategy

    Unique Go-to-Market Strategy 16 Partners supported through a complete business solution model PE-backed Group Partnership accounts represent 37% of XTRAC domestic recurring accounts

  17. Slide 17: Co-op Marketing And Practice-generated Content Creates Additional Awareness

    Co-op Marketing And Practice-generated Content Creates Additional Awareness 17 Branded promotional materials for in-office use & patient awareness Patient Brochures Counter Cards Waiting Room Videos Digital branded assets for practice web page & social media platforms Email Blasts Social Media Posts

  18. Slide 18: DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics

    DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics 18 PATIENT JOURNEY Patients see XTRAC ad on Facebook, Google and Instagram Click on the ad to go to an XTRAC page and leave their contact information In-house call center team confirms appointment and insurance benefits Pa

  19. Slide 19: DTC Core Driver for Recurring Revenue

    DTC Core Driver for Recurring Revenue 19 DTC drives patient population in the clinic at a 2:1 ratio, increasing organic prescribed patients (Halo Effect).

  20. Slide 20: Domestic XTRAC Installed Base Growth Drivers

    Domestic XTRAC® Installed Base Growth Drivers 838 2,361 358 As of 9/30/2025 Signed strategic expansion into group clinic rollups Within the 43 groups: 90 TheraClear®X devices Penetration grew from 86 in 2018 to 358 in 2024 Group partnership accounts represent 37% of XTRAC® domestic recurring revenue

  21. Slide 21: 3Q25 Financial Highlights

    3Q25 Financial Highlights 21 Revenue Total revenue $6.9M (-21% YOY) vs. $8.8M 3Q24, primarily due to challenging international markets; underlying demand remains strong across regions and growth expectations remain Global net recurring revenue $5.5M (+3% YOY) US gross recurring billings per device o

  22. Slide 22: International Sales Operations

    International Sales Operations India Israel S. Korea Japan China Bahrain, Iraq, Jordan, Kuwait, Qatar, Oman, Saudi Arabia, UAE Mexico In-house Head of International Sales 51 international partner XTRAC® clinics (S. Korea, Japan) as of September 2025 Capital equipment sales preferred model rather tha

  23. Slide 23: Affiliated Academic Institutions

    Affiliated Academic Institutions STRATA has placed over 50 XTRAC® machines in residency programs across academic institutions 23 Affiliated Academic Institutions​ STRATA devices are available at over 50 academic institutes that offer dermatology residency programs 23

  24. Slide 24: XTRAC for Psoriasis, Vitiligo, and Eczema

    XTRAC for Psoriasis, Vilitigo, and Eczema

  25. Slide 25: XTRAC: Overview

    XTRAC®: Overview Safe, effective treatment 350+ peer-reviewed clinical studies Psoriasis treatment is the number 1 domestic use for XTRAC® lasers – 80% of treatments Opportunities exist for expanding use for other approved indications like vitiligo and eczema Clinical support team focused on: In-off

  26. Slide 26: Indicated for Chronic Dermatological Diseases

    Indicated for Chronic Dermatological Diseases Visible skin disorders can limit healthy psychosocial development and have profoundly negative consequences on quality of life3-5 VITILIGO ~7.5 million adults in the US1,a PSORIASIS ATOPIC DERMATITIS ~2–3 million adults in the US2 ~16.5 million adults in

  27. Slide 27: Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques

    Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques 27 Baseline After 2 tx After 4 tx XTRAC® Psoriasis Clinical Protocol - 6.2 treatments to PASI* 75 Induces apoptosis in T cells and keratinocytes1 T cell Keratinocytes Psoriasis: Autoimmune disease that causes the skin to regenerate

  28. Slide 28: Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches

    Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches 28 Baseline After 18 tx After 21 tx XTRAC® Vitiligo Clinical Protocol - >75% repigmentation in less than 20 treatments1 Vitiligo: An autoimmune condition due to a loss of melanocytes, characterized by white patches of skin los

  29. Slide 29: XTRAC is a Preferred Treatment for 90% of Psoriasis Patients

    Source: National Psoriasis Foundation XTRAC® is a Preferred Treatment for 90% of Psoriasis Patients (<10% BSA) 29

  30. Slide 30: Has Clinical and Economic Competitive Advantage

    Has Clinical and Economic Competitive Advantage 30 XTRAC® NB-UVB Topical Steroids Non-Biologic Systemics Biologics Approximate Costs ($) 1K-3K 3K-9K 1K-7K 1K 32K-68K Clinical Outcomes 92% 71% 75% 48% 50-70% Speed of Onset 5 10 3 14 12 Days of Actual Care 18 80 294 52 12-65 Remission 2.5 Months Conti

  31. Slide 31: TheraClearX for Acne

    TheraClearX for Acne SU

  32. Slide 32: TheraClear X: Overview

    TheraClear®X: Overview Safe, effective treatment Peer-reviewed clinical studies Opportunities exist for expanding use for expanding the installed base to clinics using reimbursed acne surgery procedures Clinical support team focused on: In-office training Best practices 32

  33. Slide 33: Acne is the Most Common Skin Condition in Dermatology

    Acne is the Most Common Skin Condition in Dermatology Up to 50 Million Americans affected annually2 ~85% of all adolescents experience some degree of acne from the ages of 12 to 24 years3 >50% of US women experience acne in their 20s4 Acne occurring in adults is increasing5 #1 skin disease in the US

  34. Slide 34: Photopneumatic Technology Combines Vacuum with Pulsed Broadband Light

    Photopneumatic Technology Combines VACUUM with PULSED BROADBAND LIGHT 34 Clears bacteria and follicular contents from pilosebaceous unit, C acnes are removed both mechanically and thermally from the active acne lesion. Reduces sebum production cleans pores by extracting sebaceous and follicular mate

  35. Slide 35: Addresses Limitations of Existing Acne Therapies

    Addresses Limitations of Existing Acne Therapies 35 Visible improvement of acne lesions as early as after second treatment Visible improvement of skin texture, pore size, and perilesional erythema after the first few treatments Time to improvement Initiation 4 to 6 treatments, scheduled 1-2 weeks ap

  36. Slide 36: Seasoned Management Team

    Seasoned Management Team Sales and Operational Dermatology Experience Chief Executive Officer Dr. Dolev Rafaeli V.P. Finance John Gillings Chief Operating Officer Shmuel Gov 36

  37. Slide 37: Investment Highlights

    Investment Highlights 37 Global leader in advanced laser and light-based devices delivering unmatched efficacy and safety for serious skin disorders Existing Business is Operationally Cashflow Positive Cash from operations in 2024 was $0.2M Adjusting for 1x other income from the CARES Act of $0.9M a

  38. Slide 38: References

    References 38 XTRAC 510K Summary. Published January 14, 2020. Niwa Y, Hasegawa T, Ko S, et al. Efficacy of 308-nm excimer light for Japanese patients with psoriasis. J Dermatol. 2009;36(11):579-582. Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psori

  39. Slide 39: For More Information

    For More Information Investor Contact: CORE IR 516-222-2560 IR@strataskin.com www.strataskinsciences.com Thank You.

  40. Slide 40: Appendix

    APPENDIX SKIN SCIENCES

  41. Slide 41: Provider engagement and education through conferences and webinars

    Provider engagement and education and through conferences/ webinars 41 AAD Global Vitiligo Foundation CalDerm Fall Clinical

  42. Slide 42: Acquisitions to Drive Top-line Growth

    Acquisitions to Drive Top-line Growth January 2022 August 2021 $3.7M Acquisition Minimal acquisition cost compared to exclusivity in external laser market $1M Acquisition Adds attractive business segment to address $5.5B acne market 42

  43. Slide 43: Example – NYC Metro Area XTRAC Placements and DTC Leads (2H24)

    Example – NYC Metro Area XTRAC® Placements and DTC Leads (2H24) 43 Metro NYC XTRAC® installed base Metro NYC 2H24 DTC Patient Leads

  44. Slide 44: Psoriasis Case Study: Patient I.B., Lewisburg, PA

    Psoriasis Case Study: Patient I.B., Lewisburg, PA 44 Treatment Room After Before

STRATA Skin Sciences — Investor Presentation (December 2025) on 6ix